Save

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

PHASE3RECRUITING

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.

Simpliy with AI

Study details:

This is a Phase 3, open-label, randomized clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with advanced (inoperable) or metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Gedatolisib is an intravenously administered pan-PI3K/mTOR inhibitor. Palbociclib is a CDK4/6 inhibitor.

Fulvestrant is a selective estrogen receptor degrader (SERD). Subjects will be assessed for PIK3CA status and then randomized to treatment arms according to their confirmed PIK3CA mutation status.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Histologically or cytologically confirmed diagnosis of metastatic or locally advanced breast cancer Adult females, pre- and/or post-menopausal, and adult males. Pre-menopausal (and peri-menopausal) women can be enrolled if amenable to treatment with an LHRH agonist. Patients are to have commenced concomitant treatment with LHRH agonist prior to or on Cycle 1, Day 1 and must be willing to continue on it for the duration of the study.

Negative pregnancy test for women of childbearing potential. Female subjects of childbearing potential must use an effective and/or acceptable contraceptive method from screening until 1 year after the last dose of study treatment.

Confirmed diagnosis of estrogen receptor positive and/or progesterone receptor positive, as per American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines (2020), based on most recent tumor biopsy utilizing an assay consistent with local standards.

Documented HER2 immunohistochemistry (IHC) negative as per ASCO-CAP 2018 guidance.

Adequate archival or fresh tumor tissue for the analysis of PIK3CA mutational status.

Subject must have documentation of radiological disease progression on or after the last prior treatment and also have radiologically evaluable disease (measurable and/or non-measurable) according to RECIST v1.1, per local assessment. Subjects with bone only disease must have lytic or mixed lytic/blastic lesions that can be accurately assessed; bone only blastic lesions with no soft tissue component is not allowed.

Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

Life expectancy of at least 3 months.

Progressed during or after CDK4/6 inhibitor combination treatment with non-steroidal aromatase inhibitor (AI).

Adequate bone marrow, hepatic, renal and coagulation function.

Exclusion criteria

History of malignancies other than adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥3 years.

Prior treatment with a phosphoinositide 3-kinase (PI3K) inhibitor, a protein kinase B (Akt) inhibitor, or a mechanistic target of rapamycin (mTOR) inhibitor.

Prior treatment with chemotherapy and antibody drug conjugates for advanced disease is not permitted (prior adjuvant or neoadjuvant chemotherapy is permitted).

More than 2 lines of prior endocrine therapy treatment.

Bone only disease that is only blastic with no soft tissue component.

Subjects with type 1 diabetes or uncontrolled type 2 diabetes.

Known and untreated, or active, brain or leptomeningeal metastases. a. Subjects with previously treated central nervous system (CNS) metastases may be enrolled in the study if they meet the following criteria: do not require supportive therapy with steroids; do not have seizures and do not exhibit uncontrolled neurological symptoms; stable disease confirmed by radiographic assessment within at least 4 weeks prior to enrollment.

Patients with advanced, symptomatic, visceral spread that are at risk of life-threatening complication in the short-term.

History of clinically significant cardiovascular abnormalities such as: Congestive heart failure (New York Heart Association (NYHA) classification ≥ II within 6 months of study entry. 1. Myocardial infarction within 12 months of study entry. 2. History of any uncontrolled (or untreated) clinically significant cardiac arrhythmias, (e.g., ventricular tachycardia), complete left bundle branch block, high grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block), supraventricular, nodal arrhythmias, or conduction abnormality in the previous 12 months. 3. Uncontrolled hypertension defined by systolic blood pressure (SBP) ≥160 mmHg and/or diastolic blood pressure (DBP) ≥100 mmHg, with or without antihypertensive medication (initiation or adjustment of antihypertensive medication[s] is allowed prior to screening). 4. Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following: * i. Risk factors for Torsades de Pointes (TdP) including uncorrected hypokalemia or hypomagnesemia, or history of clinically significant/symptomatic bradycardia. * ii. On screening, inability to determine the corrected QT interval using Fridericia's formula (QTcF) on the ECG (i.e., unreadable or not interpretable) or QTcF >480 msec (determined by mean of triplicate ECGs at screening).

Known hypersensitivity to the study drugs or their components.

Pregnant or breast-feeding women.

Concurrent participation in another interventional clinical trial. 1. Subjects must agree not to participate in another clinical trial (other than observational) at any time during participation in VIKTORIA-1.

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2022-09-30

Primary completion: 2024-09-30

Study completion finish: 2026-09-30

Study type

TREATMENT

Phase

PHASE3

Trial ID

NCT05501886

Intervention or treatment

DRUG: Gedatolisib

DRUG: Palbociclib

DRUG: Fulvestrant

DRUG: Alpelisib

Conditions

• Breast Cancer

Condition: Breast Cancer
DRUG: Gedatolisib and other drugs
Adelaide, Not Specified, Australia and more
Sponsor: Celcuity Inc

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Adelaide Oncology & Haematology

Research sites nearby

Select from list below to view details:

Adelaide Oncology & Haematology
Adelaide, Not Specified, Australia
St Vincent's Hospital (Melbourne) Ltd
Fitzroy, Not Specified, Australia
Peninsula & South Eastern Hematology and Oncology Group (PSEHOG)
Frankston, Not Specified, Australia
Hollywood Private Hospital, Breast Cancer Research Centre
Nedlands, Not Specified, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Arm A - Patients Lacking PIK3CA Mutations (WT) Gedatolisib + Palbociclib + Fulvestrant	DRUG: Gedatolisib Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off
EXPERIMENTAL: Arm B - Patients Lacking PIK3CA Mutations (WT) Gedatolisib + Fulvestrant	DRUG: Gedatolisib Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off
ACTIVE_COMPARATOR: Arm C - Patients Lacking PIK3CA Mutations (WT) Fulvestrant	DRUG: Fulvestrant Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1
EXPERIMENTAL: Arm D - Patients with PIK3CA Mutation (MT) Gedatolisib + Palbociclib + Fulvestrant	DRUG: Gedatolisib Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off
ACTIVE_COMPARATOR: Arm E - Patients with PIK3CA Mutation (MT) Alpelisib + Fulvestrant	DRUG: Fulvestrant Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1
EXPERIMENTAL: Arm F - Patients with PIK3CA Mutation (MT) Gedatolisib + Fulvestrant	DRUG: Gedatolisib Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Progression Free Survival (PFS) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer	PFS is defined as the time from randomization to death or the first documented progression, whichever occurs first, confirmed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, as determined based on blinded independent central review (BICR)	Approximately 48 months

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Overall Survival (OS) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer	OS is defined as the length of time from randomization until the date of death from any cause method, where PFS is defined as the time from randomization to death or the first documented progression, whichever occurs first, confirmed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, as determined based on blinded independent central review (BICR)	From date of randomization to the date of death due to any cause, up to approximately 48 months
Overall Response Rate (ORR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer	Percentage of subjects who achieved an objective response according to RECIST v1.1 criteria (complete response \[CR\] or partial response \[PR\]) as assessed by BICR)	Up to approximately 48 months
Duration of Response (DOR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer	Time from the assessment of initial response (PR or better) to death or first documented disease progression as assessed by BICR, whichever occurs first	Up to approximately 48 months
Time to Response (TTR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer	Time form randomization to the first assessment of PR or better as assessed by BICR, whichever comes first	Up to approximately 48 months
Clinical Benefit Rate (CBR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer	Percentage of subjects with CR, PR, or stable disease (SD) \>24 weeks as assessed by BICR	Up to approximately 48 months
Quality of Life (QOL)Functional Assessment of Cancer Therapy - Breast Trial Outcome Index (FACT-B TOI) Questions in Patients with PIK3CA WT and PIK3CA MT Breast Cancer	The FACT-B TOI is an abbreviated (24-item) version of the full FACT-B which focuses only on the patient's Physical Well-being (PWB), Functional Well-being (FWB), and Breast Cancer Subscale (BCS) components using a 5-level scale, (Not at all, A little bit, Some-what, Quite a bit, Very much).	From baseline to 30 Day Safety Follow-up
Quality of Life (QOL) NCCN-FACT Breast Symptom Index -16 (NFBSI-16) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer	NCCN-FACT is derived from the FACT-B and only 4 additional items will be administered to enable optional scoring of the NFBSI subscales and total score using a 5-level scale (Not at all, A little bit, Some-what, Quite a bit, Very much).	From baseline to 30 Day Safety Follow-up
Patient-Reported Outcomes in Patients with PIK3CA WT and PIK3CA MT Breast Cancer	Patient-Reported Outcomes Measurement Information System (PROMIS®) Short Form v2.0 - Physical Function 8c using a 5-level scale (Without any difficulty, With a little difficulty, With some difficulty, With much difficulty, Unable to do)	From baseline to 30 Day Safety Follow-up
EuroQol 5 in Patients with PIK3CA WT and PIK3CA MT Breast Cancer	EuroQol 5 Dimension 5 Level (EQ-5D-5L) - This is a 5 question, self-administered visual analog scale (VAS) where patients use 0 (worst health) to 100 (best health) to indicate how they view their health.	From baseline to 30 Day Safety Follow-up
Adverse Events	Safety and tolerability will be evaluated by review of type, incidence, severity (as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] v5.0), seriousness, and relationship to study medications of adverse events (AEs) and any laboratory abnormalities	Up to approximately 48 months

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)